Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck

Shahzad Raza, Noah Kornblum, Venkat P. Kancharla, Mahadi A. Baig, Amrit B. Singh, Madhumati Kalavar

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Head and neck squamous cell cancers (HNSCCs) represent 4 to 5% of all solid malignancies. Despite improvements in diagnostic techniques, 60% of patients will present with locally advanced HNSCCs with a median survival of about 12 months and 5-year overall survival of approximately 10-40%. Recent clinical trials have altered the treatment landscape by refining existing forms of radiation, incorporation of IMRT, choice of chemotherapeutic agents, introduction of biological and targeted therapy, immunotherapy and gene therapy. Cetuximab, a monoclonal antibody directed against the human epidermal growth factor receptor (EGFR), has recently been approved in combination with RT in patients with locally advanced HNSCCs. Antiangiogenic therapies and tyrosine kinase inhibitors (gefitinib and erlotinib) have also shown promise in the clinical trials. Vandetanib, an antagonist of both vascular endothelial growth factor receptor (VEGFR) and the EGFR is currently being tested in phase II trial. New patents on hypoxia-inducible factor 1 alpha, mesenchymal-epithelial transition factor, insulin-like growth factor or the PI3K/AKT/mTOR pathway, farnesyl transferase inhibitors have shown promise in the management of HNSCCs. Nevertheless, identification of predictive biomarkers of resistance or sensitivity to these therapies remains a fundamental challenge in the optimal selection of patients most likely to benefit from them. However, increase in efficacy comes at the cost of increased toxicity. The current review focuses on insight into recent patents and updates on the clinical trials using new investigational agents in the management for HNSCCs.

Original languageEnglish (US)
Pages (from-to)246-257
Number of pages12
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume6
Issue number2
DOIs
StatePublished - 2011

Fingerprint

Squamous Cell Neoplasms
Head and Neck Neoplasms
Head
Patents
Clinical Trials
Epidermal Growth Factor Receptor
Therapeutics
Hypoxia-Inducible Factor 1
Biological Therapy
Vascular Endothelial Growth Factor Receptor
Epithelial-Mesenchymal Transition
Survival
Somatomedins
Transferases
Phosphatidylinositol 3-Kinases
Genetic Therapy
Protein-Tyrosine Kinases
Immunotherapy
Patient Selection
Biomarkers

Keywords

  • Antiangiogenic therapies
  • Cetuximab
  • Epidermal growth factor inhibitors
  • Intensity modulated radiation therapy
  • Vascular endothelial growth factors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)
  • Drug Discovery

Cite this

Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck. / Raza, Shahzad; Kornblum, Noah; Kancharla, Venkat P.; Baig, Mahadi A.; Singh, Amrit B.; Kalavar, Madhumati.

In: Recent Patents on Anti-Cancer Drug Discovery, Vol. 6, No. 2, 2011, p. 246-257.

Research output: Contribution to journalArticle

Raza, Shahzad ; Kornblum, Noah ; Kancharla, Venkat P. ; Baig, Mahadi A. ; Singh, Amrit B. ; Kalavar, Madhumati. / Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck. In: Recent Patents on Anti-Cancer Drug Discovery. 2011 ; Vol. 6, No. 2. pp. 246-257.
@article{f582220649ba4129852603c60e942b5b,
title = "Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck",
abstract = "Head and neck squamous cell cancers (HNSCCs) represent 4 to 5{\%} of all solid malignancies. Despite improvements in diagnostic techniques, 60{\%} of patients will present with locally advanced HNSCCs with a median survival of about 12 months and 5-year overall survival of approximately 10-40{\%}. Recent clinical trials have altered the treatment landscape by refining existing forms of radiation, incorporation of IMRT, choice of chemotherapeutic agents, introduction of biological and targeted therapy, immunotherapy and gene therapy. Cetuximab, a monoclonal antibody directed against the human epidermal growth factor receptor (EGFR), has recently been approved in combination with RT in patients with locally advanced HNSCCs. Antiangiogenic therapies and tyrosine kinase inhibitors (gefitinib and erlotinib) have also shown promise in the clinical trials. Vandetanib, an antagonist of both vascular endothelial growth factor receptor (VEGFR) and the EGFR is currently being tested in phase II trial. New patents on hypoxia-inducible factor 1 alpha, mesenchymal-epithelial transition factor, insulin-like growth factor or the PI3K/AKT/mTOR pathway, farnesyl transferase inhibitors have shown promise in the management of HNSCCs. Nevertheless, identification of predictive biomarkers of resistance or sensitivity to these therapies remains a fundamental challenge in the optimal selection of patients most likely to benefit from them. However, increase in efficacy comes at the cost of increased toxicity. The current review focuses on insight into recent patents and updates on the clinical trials using new investigational agents in the management for HNSCCs.",
keywords = "Antiangiogenic therapies, Cetuximab, Epidermal growth factor inhibitors, Intensity modulated radiation therapy, Vascular endothelial growth factors",
author = "Shahzad Raza and Noah Kornblum and Kancharla, {Venkat P.} and Baig, {Mahadi A.} and Singh, {Amrit B.} and Madhumati Kalavar",
year = "2011",
doi = "10.2174/157489211795328477",
language = "English (US)",
volume = "6",
pages = "246--257",
journal = "Recent Patents on Anti-Cancer Drug Discovery",
issn = "1574-8928",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck

AU - Raza, Shahzad

AU - Kornblum, Noah

AU - Kancharla, Venkat P.

AU - Baig, Mahadi A.

AU - Singh, Amrit B.

AU - Kalavar, Madhumati

PY - 2011

Y1 - 2011

N2 - Head and neck squamous cell cancers (HNSCCs) represent 4 to 5% of all solid malignancies. Despite improvements in diagnostic techniques, 60% of patients will present with locally advanced HNSCCs with a median survival of about 12 months and 5-year overall survival of approximately 10-40%. Recent clinical trials have altered the treatment landscape by refining existing forms of radiation, incorporation of IMRT, choice of chemotherapeutic agents, introduction of biological and targeted therapy, immunotherapy and gene therapy. Cetuximab, a monoclonal antibody directed against the human epidermal growth factor receptor (EGFR), has recently been approved in combination with RT in patients with locally advanced HNSCCs. Antiangiogenic therapies and tyrosine kinase inhibitors (gefitinib and erlotinib) have also shown promise in the clinical trials. Vandetanib, an antagonist of both vascular endothelial growth factor receptor (VEGFR) and the EGFR is currently being tested in phase II trial. New patents on hypoxia-inducible factor 1 alpha, mesenchymal-epithelial transition factor, insulin-like growth factor or the PI3K/AKT/mTOR pathway, farnesyl transferase inhibitors have shown promise in the management of HNSCCs. Nevertheless, identification of predictive biomarkers of resistance or sensitivity to these therapies remains a fundamental challenge in the optimal selection of patients most likely to benefit from them. However, increase in efficacy comes at the cost of increased toxicity. The current review focuses on insight into recent patents and updates on the clinical trials using new investigational agents in the management for HNSCCs.

AB - Head and neck squamous cell cancers (HNSCCs) represent 4 to 5% of all solid malignancies. Despite improvements in diagnostic techniques, 60% of patients will present with locally advanced HNSCCs with a median survival of about 12 months and 5-year overall survival of approximately 10-40%. Recent clinical trials have altered the treatment landscape by refining existing forms of radiation, incorporation of IMRT, choice of chemotherapeutic agents, introduction of biological and targeted therapy, immunotherapy and gene therapy. Cetuximab, a monoclonal antibody directed against the human epidermal growth factor receptor (EGFR), has recently been approved in combination with RT in patients with locally advanced HNSCCs. Antiangiogenic therapies and tyrosine kinase inhibitors (gefitinib and erlotinib) have also shown promise in the clinical trials. Vandetanib, an antagonist of both vascular endothelial growth factor receptor (VEGFR) and the EGFR is currently being tested in phase II trial. New patents on hypoxia-inducible factor 1 alpha, mesenchymal-epithelial transition factor, insulin-like growth factor or the PI3K/AKT/mTOR pathway, farnesyl transferase inhibitors have shown promise in the management of HNSCCs. Nevertheless, identification of predictive biomarkers of resistance or sensitivity to these therapies remains a fundamental challenge in the optimal selection of patients most likely to benefit from them. However, increase in efficacy comes at the cost of increased toxicity. The current review focuses on insight into recent patents and updates on the clinical trials using new investigational agents in the management for HNSCCs.

KW - Antiangiogenic therapies

KW - Cetuximab

KW - Epidermal growth factor inhibitors

KW - Intensity modulated radiation therapy

KW - Vascular endothelial growth factors

UR - http://www.scopus.com/inward/record.url?scp=79954470620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954470620&partnerID=8YFLogxK

U2 - 10.2174/157489211795328477

DO - 10.2174/157489211795328477

M3 - Article

VL - 6

SP - 246

EP - 257

JO - Recent Patents on Anti-Cancer Drug Discovery

JF - Recent Patents on Anti-Cancer Drug Discovery

SN - 1574-8928

IS - 2

ER -